Since the discovery of the benefit of EGFR-targeted monoclonal antibody therapy in patients with KRAS wild-type metastatic colorectal cancer (Karapetis et al, 2008), it has become increasingly important to understand the mechanisms operating in tumours that eventually develop drug resistance. The gene discussed is EGFR; the disease is neoplasm.